You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolbutamide
Accession NumberDB01124  (APRD00267)
TypeSmall Molecule
GroupsApproved
DescriptionTolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Structure
Thumb
Synonyms
1-Butyl-3-(P-methylphenylsulfonyl)urea
1-Butyl-3-(P-tolylsulfonyl)urea
1-Butyl-3-tosylurea
1-P-Toluenesulfonyl-3-butylurea
3-(P-Tolyl-4-sulfonyl)-1-butylurea
N-(4-Methylbenzenesulfonyl)-n'-butylurea
N-(4-Methylphenylsulfonyl)-n'-butylurea
N-(P-Methylbenzenesulfonyl)-n'-butylurea
N-(Sulfonyl-P-methylbenzene)-n'-N-butylurea
N-Butyl-n'-(4-methylphenylsulfonyl)urea
N-Butyl-N'-(p-tolylsulfonyl)urea
N-Butyl-n'-P-toluenesulfonylurea
N-N-Butyl-n'-tosylurea
Orinase (tn)
Tolbutamida
Tolbutamide
Tolbutamidum
Tolylsulfonylbutylurea
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mobenol Tablets 500mgtablet500 mgoralCarter Horner Corp.1957-12-311997-08-14Canada
Novo-butamide 500mgtablet500 mgoralNovopharm Limited1968-12-312005-08-10Canada
Orinase 0.5gmtablet500 mgoralHoechst Canada Inc.1957-12-311997-02-28Canada
Orinase 1gmtablet1 goralHoechst Canada Inc.1966-12-311997-02-28Canada
Tolbutamidetablet500 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Tolbutamide Tab 500mgtablet500 mgoralPro Doc Limitee1962-12-312010-07-13Canada
Tolbutamide Tab 500mgtablet500 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tolbutamidetablet500 mg/1oralMylan Pharmaceuticals Inc.1989-11-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArtosinNot Available
ButamideNot Available
DiabetolNot Available
DirastanNot Available
GlycononNot Available
OrinaseNot Available
RastinonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tolbutamide sodium
ThumbNot applicableDBSALT001412
Categories
UNII982XCM1FOI
CAS number64-77-7
WeightAverage: 270.348
Monoisotopic: 270.103813142
Chemical FormulaC12H18N2O3S
InChI KeyInChIKey=JLRGJRBPOGGCBT-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
IUPAC Name
3-butyl-1-(4-methylbenzenesulfonyl)urea
SMILES
CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Tosyl compound
  • Benzenesulfonamide
  • Toluene
  • Sulfonylurea
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.
PharmacodynamicsTolbutamide, a first-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Tolbutamide is twice as potent as the related second-generation agent glipizide. Tolbutamide lowers blood sugar by stimulating the pancreas to secrete insulin and helping the body use insulin efficiently. The pancreas must be able to produce insulin for this drug to work.
Mechanism of actionSulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.
Related Articles
AbsorptionReadily absorbed following oral administration. Tolbutamide is detectable in plasma 30-60 minutes following oral administration of a single dose with peak plasma concentrations occurring within 3-5 hours. Absorption is unaltered if taken with food but is increased with high pH.
Volume of distributionNot Available
Protein bindingApproximately 95% bound to plasma proteins.
Metabolism

Metabolized in the liver principally via oxidation of the p-methyl group producing the carboxyl metabolite, 1-butyl-3-p-carboxyphenylsulfonylurea. May also be metabolized to hydroxytolbutamide. Tolbutamide does not undergo acetylation like antibacterial sulfonamides as it does not have a p-amino group.

SubstrateEnzymesProduct
Tolbutamide
4-Hydroxy tolbutamideDetails
Route of eliminationUnchanged drug and metabolites are eliminated in the urine and feces. Approximately 75-85% of a single orally administered dose is excreted in the urine principally as the 1-butyl-3-p-carboxyphenylsulfonylurea within 24 hours.
Half lifeApproximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.
ClearanceNot Available
ToxicityOral, mouse: LD50 = 2600 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712
rs1057910 CYP2C9*1C AllelePoor drug metabolizer, lower dose requirements8873220
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9321
Caco-2 permeable-0.6453
P-glycoprotein substrateNon-substrate0.5333
P-glycoprotein inhibitor INon-inhibitor0.9349
P-glycoprotein inhibitor IINon-inhibitor0.9131
Renal organic cation transporterNon-inhibitor0.8852
CYP450 2C9 substrateSubstrate0.5304
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9443
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9504
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9613
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.881
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.781
BiodegradationNot ready biodegradable0.8811
Rat acute toxicity2.0629 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9561
hERG inhibition (predictor II)Non-inhibitor0.9511
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 g
Tabletoral500 mg/1
Tabletoral500 mg
Prices
Unit descriptionCostUnit
Tolbutamide 500 mg tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point128.5 °CPhysProp
water solubility109 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.34HANSCH,C ET AL. (1995)
logS-3.39ADME Research, USCD
pKa5.16SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.202 mg/mLALOGPS
logP2.04ALOGPS
logP2.3ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity70.27 m3·mol-1ChemAxon
Polarizability29.1 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.12 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yan-Ping Chen, Pai-Ching Lin, “Tolbutamide Particle And Preparing Method Thereof And Method Of Reducing A Blood Glucose.” U.S. Patent US20120121707, issued May 17, 2012.

US20120121707
General References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
External Links
ATC CodesA10BB03V04CA01
AHFS Codes
  • 68:20.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.9 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Tolbutamide.
AbirateroneThe serum concentration of Tolbutamide can be increased when it is combined with Abiraterone.
AcarboseAcarbose may increase the hypoglycemic activities of Tolbutamide.
AcebutololAcebutolol may increase the hypoglycemic activities of Tolbutamide.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Tolbutamide.
AcenocoumarolTolbutamide may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Tolbutamide.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Tolbutamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Tolbutamide.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Tolbutamide.
AicarAicar may increase the hypoglycemic activities of Tolbutamide.
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Tolbutamide.
AlogliptinAlogliptin may increase the hypoglycemic activities of Tolbutamide.
AlosetronThe metabolism of Alosetron can be decreased when combined with Tolbutamide.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Tolbutamide.
AlprenololAlprenolol may increase the hypoglycemic activities of Tolbutamide.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tolbutamide.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Tolbutamide.
AmiodaroneThe metabolism of Tolbutamide can be decreased when combined with Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Tolbutamide.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Tolbutamide.
AmoxapineAmoxapine may increase the hypoglycemic activities of Tolbutamide.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Tolbutamide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Tolbutamide.
ApixabanThe metabolism of Apixaban can be decreased when combined with Tolbutamide.
AprepitantThe serum concentration of Tolbutamide can be decreased when it is combined with Aprepitant.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Tolbutamide.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Tolbutamide.
AripiprazoleThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.
ArmodafinilThe metabolism of Tolbutamide can be decreased when combined with Armodafinil.
ArotinololArotinolol may increase the hypoglycemic activities of Tolbutamide.
Arsenic trioxideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Arsenic trioxide.
ArtemetherThe metabolism of Artemether can be decreased when combined with Tolbutamide.
ArticaineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Tolbutamide.
AtenololAtenolol may increase the hypoglycemic activities of Tolbutamide.
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Tolbutamide.
AzelastineThe metabolism of Azelastine can be decreased when combined with Tolbutamide.
BefunololBefunolol may increase the hypoglycemic activities of Tolbutamide.
BendroflumethiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Tolbutamide.
BetamethasoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Betamethasone.
BetaxololBetaxolol may increase the hypoglycemic activities of Tolbutamide.
BevantololBevantolol may increase the hypoglycemic activities of Tolbutamide.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Tolbutamide.
BezafibrateBezafibrate may increase the hypoglycemic activities of Tolbutamide.
BisoprololBisoprolol may increase the hypoglycemic activities of Tolbutamide.
BopindololBopindolol may increase the hypoglycemic activities of Tolbutamide.
BortezomibThe metabolism of Tolbutamide can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Tolbutamide.
BrexpiprazoleThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Brexpiprazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Tolbutamide.
BuforminBuformin may increase the hypoglycemic activities of Tolbutamide.
BufuralolBufuralol may increase the hypoglycemic activities of Tolbutamide.
BumetanideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bumetanide.
BupranololBupranolol may increase the hypoglycemic activities of Tolbutamide.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Tolbutamide.
BupropionThe metabolism of Bupropion can be decreased when combined with Tolbutamide.
BuserelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Buserelin.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Tolbutamide.
CaffeineThe metabolism of Caffeine can be decreased when combined with Tolbutamide.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Tolbutamide.
CandesartanThe metabolism of Candesartan can be decreased when combined with Tolbutamide.
CapecitabineThe metabolism of Tolbutamide can be decreased when combined with Capecitabine.
CarbamazepineThe metabolism of Tolbutamide can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Tolbutamide.
CarbocisteineThe risk or severity of adverse effects can be increased when Tolbutamide is combined with Carbocisteine.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Tolbutamide.
CarteololCarteolol may increase the hypoglycemic activities of Tolbutamide.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Tolbutamide.
CarvedilolCarvedilol may increase the hypoglycemic activities of Tolbutamide.
CastanospermineCastanospermine may increase the hypoglycemic activities of Tolbutamide.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Tolbutamide.
CeliprololCeliprolol may increase the hypoglycemic activities of Tolbutamide.
CeritinibThe serum concentration of Tolbutamide can be increased when it is combined with Ceritinib.
ChloramphenicolThe metabolism of Tolbutamide can be decreased when combined with Chloramphenicol.
ChlorothiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorothiazide.
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Tolbutamide.
ChlorthalidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorthalidone.
CholecalciferolThe metabolism of Tolbutamide can be decreased when combined with Cholecalciferol.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Tolbutamide.
CimetidineThe serum concentration of Tolbutamide can be increased when it is combined with Cimetidine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tolbutamide.
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Tolbutamide.
CisaprideThe metabolism of Cisapride can be decreased when combined with Tolbutamide.
CitalopramCitalopram may increase the hypoglycemic activities of Tolbutamide.
ClofibrateClofibrate may increase the hypoglycemic activities of Tolbutamide.
ClomipramineClomipramine may increase the hypoglycemic activities of Tolbutamide.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Tolbutamide.
ClotrimazoleThe metabolism of Tolbutamide can be decreased when combined with Clotrimazole.
ClozapineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Clozapine.
ClozapineThe metabolism of Clozapine can be decreased when combined with Tolbutamide.
CorticotropinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cortisone acetate.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Tolbutamide.
CyclosporineThe metabolism of Tolbutamide can be decreased when combined with Cyclosporine.
Cyproterone acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Tolbutamide.
DapoxetineDapoxetine may increase the hypoglycemic activities of Tolbutamide.
DapsoneThe metabolism of Dapsone can be decreased when combined with Tolbutamide.
DarunavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Darunavir.
DeferasiroxThe serum concentration of Tolbutamide can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Tolbutamide can be decreased when combined with Delavirdine.
DesogestrelThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dexamethasone.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Tolbutamide.
DiazepamThe metabolism of Diazepam can be decreased when combined with Tolbutamide.
DiazoxideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Diazoxide.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Tolbutamide.
DicoumarolTolbutamide may increase the anticoagulant activities of Dicoumarol.
DienogestThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dienogest.
DiflunisalDiflunisal may increase the hypoglycemic activities of Tolbutamide.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Tolbutamide.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Tolbutamide.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Tolbutamide.
DisopyramideTolbutamide may increase the hypoglycemic activities of Disopyramide.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Tolbutamide.
DonepezilThe metabolism of Donepezil can be decreased when combined with Tolbutamide.
DopamineThe metabolism of Dopamine can be decreased when combined with Tolbutamide.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Tolbutamide.
DoxepinThe metabolism of Doxepin can be decreased when combined with Tolbutamide.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Tolbutamide.
DrospirenoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Drospirenone.
DulaglutideDulaglutide may increase the hypoglycemic activities of Tolbutamide.
EfavirenzThe metabolism of Tolbutamide can be decreased when combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Tolbutamide.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Tolbutamide.
EpinephrineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Epinephrine.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Tolbutamide.
EscitalopramEscitalopram may increase the hypoglycemic activities of Tolbutamide.
Eslicarbazepine acetateThe metabolism of Tolbutamide can be decreased when combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the hypoglycemic activities of Tolbutamide.
EsomeprazoleThe metabolism of Tolbutamide can be decreased when combined with Esomeprazole.
EstradiolThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Estradiol.
EstradiolThe metabolism of Estradiol can be decreased when combined with Tolbutamide.
EstroneThe metabolism of Estrone can be decreased when combined with Tolbutamide.
Estrone sulfateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Estrone sulfate.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Tolbutamide.
Etacrynic acidThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Tolbutamide is combined with Ethanol.
Ethinyl EstradiolThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethinyl Estradiol.
Ethyl biscoumacetateTolbutamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethynodiol diacetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethynodiol diacetate.
EtodolacThe metabolism of Etodolac can be decreased when combined with Tolbutamide.
EtofibrateEtofibrate may increase the hypoglycemic activities of Tolbutamide.
EtonogestrelThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Tolbutamide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Tolbutamide.
EtravirineThe metabolism of Tolbutamide can be decreased when combined with Etravirine.
EverolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Everolimus.
ExenatideExenatide may increase the hypoglycemic activities of Tolbutamide.
FelodipineThe metabolism of Tolbutamide can be decreased when combined with Felodipine.
FenfluramineFenfluramine may increase the hypoglycemic activities of Tolbutamide.
FenofibrateFenofibrate may increase the hypoglycemic activities of Tolbutamide.
FloxuridineThe metabolism of Tolbutamide can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Tolbutamide can be decreased when combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Fludrocortisone.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Tolbutamide.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Tolbutamide.
FluorouracilThe metabolism of Tolbutamide can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the hypoglycemic activities of Tolbutamide.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Tolbutamide.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Tolbutamide.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Tolbutamide.
FluvastatinThe metabolism of Tolbutamide can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Tolbutamide.
FormoterolThe metabolism of Formoterol can be decreased when combined with Tolbutamide.
FosamprenavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Fosamprenavir.
FosaprepitantThe serum concentration of Tolbutamide can be decreased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Tolbutamide can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Tolbutamide.
FurosemideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Furosemide.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Tolbutamide.
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Tolbutamide.
GlibornurideGlibornuride may increase the hypoglycemic activities of Tolbutamide.
GliclazideGliclazide may increase the hypoglycemic activities of Tolbutamide.
GlimepirideGlimepiride may increase the hypoglycemic activities of Tolbutamide.
GlipizideGlipizide may increase the hypoglycemic activities of Tolbutamide.
GliquidoneGliquidone may increase the hypoglycemic activities of Tolbutamide.
GlyburideGlyburide may increase the hypoglycemic activities of Tolbutamide.
GoserelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Tolbutamide.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Tolbutamide.
HalothaneThe metabolism of Halothane can be decreased when combined with Tolbutamide.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Tolbutamide.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Tolbutamide.
HistrelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Tolbutamide.
HydrochlorothiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydroflumethiazide.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Tolbutamide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydroxyprogesterone caproate.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Tolbutamide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Tolbutamide.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Tolbutamide.
IloperidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Iloperidone.
ImatinibThe metabolism of Imatinib can be decreased when combined with Tolbutamide.
IndalpineIndalpine may increase the hypoglycemic activities of Tolbutamide.
IndapamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indapamide.
IndenololIndenolol may increase the hypoglycemic activities of Tolbutamide.
IndinavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Tolbutamide.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Tolbutamide.
Insulin AspartTolbutamide may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirTolbutamide may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Tolbutamide.
Insulin GlulisineTolbutamide may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanTolbutamide may increase the hypoglycemic activities of Insulin Human.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Tolbutamide.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Tolbutamide.
IproclozideIproclozide may increase the hypoglycemic activities of Tolbutamide.
IproniazidIproniazid may increase the hypoglycemic activities of Tolbutamide.
IrbesartanThe metabolism of Tolbutamide can be decreased when combined with Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Tolbutamide.
IsoniazidThe metabolism of Tolbutamide can be decreased when combined with Isoniazid.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Tolbutamide.
KetamineThe metabolism of Ketamine can be decreased when combined with Tolbutamide.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Tolbutamide.
KetoconazoleThe metabolism of Tolbutamide can be decreased when combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Tolbutamide.
LabetalolLabetalol may increase the hypoglycemic activities of Tolbutamide.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Tolbutamide.
LanreotideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lanreotide.
LanreotideTolbutamide may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Tolbutamide.
LapatinibThe metabolism of Tolbutamide can be decreased when combined with Lapatinib.
LeflunomideThe serum concentration of Tolbutamide can be increased when it is combined with Leflunomide.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Tolbutamide.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Tolbutamide.
LeuprolideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.
LevobunololLevobunolol may increase the hypoglycemic activities of Tolbutamide.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Tolbutamide.
LevonorgestrelThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Levonorgestrel.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Tolbutamide.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Tolbutamide.
LinagliptinLinagliptin may increase the hypoglycemic activities of Tolbutamide.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Tolbutamide.
LiraglutideLiraglutide may increase the hypoglycemic activities of Tolbutamide.
LopinavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Tolbutamide.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Tolbutamide.
LosartanThe metabolism of Tolbutamide can be decreased when combined with Losartan.
LovastatinThe metabolism of Tolbutamide can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Tolbutamide.
LuliconazoleThe serum concentration of Tolbutamide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Tolbutamide can be decreased when it is combined with Lumacaftor.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Tolbutamide.
LurasidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone.
MebanazineMebanazine may increase the hypoglycemic activities of Tolbutamide.
MecaserminTolbutamide may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Tolbutamide.
Megestrol acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Megestrol acetate.
MelatoninThe metabolism of Melatonin can be decreased when combined with Tolbutamide.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Tolbutamide.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Tolbutamide.
MesalazineMesalazine may increase the hypoglycemic activities of Tolbutamide.
MestranolThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Mestranol.
MestranolThe metabolism of Mestranol can be decreased when combined with Tolbutamide.
MetforminMetformin may increase the hypoglycemic activities of Tolbutamide.
MethadoneThe metabolism of Methadone can be decreased when combined with Tolbutamide.
MethotrimeprazineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methotrimeprazine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Tolbutamide.
MethyclothiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.
Methylene blueMethylene blue may increase the hypoglycemic activities of Tolbutamide.
MethylprednisoloneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methylprednisolone.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Tolbutamide.
MetipranololMetipranolol may increase the hypoglycemic activities of Tolbutamide.
MetolazoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone.
MetoprololMetoprolol may increase the hypoglycemic activities of Tolbutamide.
MetreleptinMetreleptin may increase the hypoglycemic activities of Tolbutamide.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Tolbutamide.
MiconazoleMiconazole may increase the hypoglycemic activities of Tolbutamide.
MifepristoneTolbutamide may increase the hypoglycemic activities of Mifepristone.
MiglitolMiglitol may increase the hypoglycemic activities of Tolbutamide.
MiglustatMiglustat may increase the hypoglycemic activities of Tolbutamide.
MilnacipranMilnacipran may increase the hypoglycemic activities of Tolbutamide.
MinaprineMinaprine may increase the hypoglycemic activities of Tolbutamide.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Tolbutamide.
MitiglinideMitiglinide may increase the hypoglycemic activities of Tolbutamide.
MoclobemideMoclobemide may increase the hypoglycemic activities of Tolbutamide.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Tolbutamide.
ModafinilThe metabolism of Tolbutamide can be decreased when combined with Modafinil.
MontelukastThe metabolism of Montelukast can be decreased when combined with Tolbutamide.
NadololNadolol may increase the hypoglycemic activities of Tolbutamide.
NaproxenThe metabolism of Naproxen can be decreased when combined with Tolbutamide.
NateglinideNateglinide may increase the hypoglycemic activities of Tolbutamide.
NelfinavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Nelfinavir.
NetupitantThe metabolism of Netupitant can be decreased when combined with Tolbutamide.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Tolbutamide.
NiacinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Tolbutamide.
NicardipineThe metabolism of Tolbutamide can be decreased when combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Tolbutamide.
NicotineThe metabolism of Nicotine can be decreased when combined with Tolbutamide.
NilotinibThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Norgestimate.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Tolbutamide.
OctamoxinOctamoxin may increase the hypoglycemic activities of Tolbutamide.
OctreotideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Octreotide.
OctreotideTolbutamide may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Tolbutamide.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Tolbutamide.
OmeprazoleThe metabolism of Tolbutamide can be decreased when combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Tolbutamide.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Tolbutamide.
OxandroloneOxandrolone may increase the hypoglycemic activities of Tolbutamide.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Tolbutamide.
OxprenololOxprenolol may increase the hypoglycemic activities of Tolbutamide.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Tolbutamide.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Tolbutamide.
PaliperidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.
PantoprazoleThe metabolism of Tolbutamide can be decreased when combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Tolbutamide.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Tolbutamide.
PargylinePargyline may increase the hypoglycemic activities of Tolbutamide.
ParoxetineParoxetine may increase the hypoglycemic activities of Tolbutamide.
PasireotideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pasireotide.
PasireotideTolbutamide may increase the hypoglycemic activities of Pasireotide.
PegvisomantPegvisomant may increase the hypoglycemic activities of Tolbutamide.
PenbutololPenbutolol may increase the hypoglycemic activities of Tolbutamide.
PentamidineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pentamidine.
PentamidineTolbutamide may increase the hypoglycemic activities of Pentamidine.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Tolbutamide.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Tolbutamide.
PhenelzinePhenelzine may increase the hypoglycemic activities of Tolbutamide.
PhenforminPhenformin may increase the hypoglycemic activities of Tolbutamide.
PhenindioneTolbutamide may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the hypoglycemic activities of Tolbutamide.
PhenobarbitalThe metabolism of Tolbutamide can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Tolbutamide.
PhenprocoumonTolbutamide may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Tolbutamide.
PhenytoinThe metabolism of Tolbutamide can be increased when combined with Phenytoin.
PindololPindolol may increase the hypoglycemic activities of Tolbutamide.
PioglitazonePioglitazone may increase the hypoglycemic activities of Tolbutamide.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Tolbutamide.
PiperazineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pipotiazine.
PirlindolePirlindole may increase the hypoglycemic activities of Tolbutamide.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Tolbutamide.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Tolbutamide.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Tolbutamide.
PolythiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Polythiazide.
PractololPractolol may increase the hypoglycemic activities of Tolbutamide.
PramlintidePramlintide may increase the hypoglycemic activities of Tolbutamide.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Tolbutamide.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Tolbutamide.
PrednisoloneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisone.
PrimidoneThe metabolism of Tolbutamide can be increased when combined with Primidone.
ProbenecidThe protein binding of Tolbutamide can be decreased when combined with Probenecid.
ProgesteroneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Progesterone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tolbutamide.
ProguanilThe metabolism of Proguanil can be decreased when combined with Tolbutamide.
PromazineThe metabolism of Promazine can be decreased when combined with Tolbutamide.
PropofolThe metabolism of Propofol can be decreased when combined with Tolbutamide.
PropranololPropranolol may increase the hypoglycemic activities of Tolbutamide.
PyrimethamineThe metabolism of Tolbutamide can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Tolbutamide.
QuetiapineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quetiapine.
QuinethazoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quinethazone.
QuinidineThe metabolism of Quinidine can be decreased when combined with Tolbutamide.
QuinineTolbutamide may increase the hypoglycemic activities of Quinine.
RabeprazoleThe metabolism of Tolbutamide can be decreased when combined with Rabeprazole.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Tolbutamide.
RanitidineThe serum concentration of Tolbutamide can be increased when it is combined with Ranitidine.
RasagilineRasagiline may increase the hypoglycemic activities of Tolbutamide.
RepaglinideRepaglinide may increase the hypoglycemic activities of Tolbutamide.
RifampicinThe serum concentration of Tolbutamide can be decreased when it is combined with Rifampicin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Tolbutamide.
RifapentineThe metabolism of Tolbutamide can be increased when combined with Rifapentine.
RisperidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ritonavir.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Tolbutamide.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Tolbutamide.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Tolbutamide.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Tolbutamide.
SafrazineSafrazine may increase the hypoglycemic activities of Tolbutamide.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Tolbutamide.
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Tolbutamide.
SaquinavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Tolbutamide.
SecobarbitalThe metabolism of Tolbutamide can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypoglycemic activities of Tolbutamide.
SelegilineThe metabolism of Selegiline can be decreased when combined with Tolbutamide.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Tolbutamide.
SertralineSertraline may increase the hypoglycemic activities of Tolbutamide.
SertralineThe metabolism of Sertraline can be decreased when combined with Tolbutamide.
SildenafilThe metabolism of Tolbutamide can be decreased when combined with Sildenafil.
SirolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Sirolimus.
SitagliptinSitagliptin may increase the hypoglycemic activities of Tolbutamide.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Tolbutamide.
SorafenibThe metabolism of Tolbutamide can be decreased when combined with Sorafenib.
SotalolSotalol may increase the hypoglycemic activities of Tolbutamide.
StanozololStanozolol may increase the hypoglycemic activities of Tolbutamide.
StiripentolThe metabolism of Tolbutamide can be decreased when combined with Stiripentol.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Tolbutamide.
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Tolbutamide.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Tolbutamide.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Tolbutamide.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Tolbutamide.
SulodexideSulodexide may increase the hypoglycemic activities of Tolbutamide.
SunitinibTolbutamide may increase the hypoglycemic activities of Sunitinib.
SuprofenThe metabolism of Suprofen can be decreased when combined with Tolbutamide.
TacrolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tacrolimus.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Tolbutamide.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Tolbutamide.
TemazepamThe metabolism of Temazepam can be decreased when combined with Tolbutamide.
TemsirolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Temsirolimus.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Tolbutamide.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Tolbutamide.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Tolbutamide.
TeriflunomideThe metabolism of Tolbutamide can be decreased when combined with Teriflunomide.
TestosteroneTestosterone may increase the hypoglycemic activities of Tolbutamide.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Tolbutamide.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Tolbutamide.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Tolbutamide.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Tolbutamide.
TicagrelorThe metabolism of Tolbutamide can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Tolbutamide can be decreased when combined with Ticlopidine.
TimololTimolol may increase the hypoglycemic activities of Tolbutamide.
TipranavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tipranavir.
TolazamideTolazamide may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Tolbutamide.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Tolbutamide.
TopiramateThe metabolism of Tolbutamide can be decreased when combined with Topiramate.
TorasemideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Torasemide.
TorasemideThe metabolism of Torasemide can be decreased when combined with Tolbutamide.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Tolbutamide.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolbutamide.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Tolbutamide.
TrazodoneTrazodone may increase the hypoglycemic activities of Tolbutamide.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Tolbutamide.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Tolbutamide.
TriamcinoloneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Trichlormethiazide.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Tolbutamide.
TrimethoprimThe metabolism of Tolbutamide can be decreased when combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Tolbutamide.
TriptorelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triptorelin.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Tolbutamide.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Tolbutamide.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Tolbutamide.
Valproic AcidThe metabolism of Tolbutamide can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Tolbutamide can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Tolbutamide.
VerapamilThe metabolism of Verapamil can be decreased when combined with Tolbutamide.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Tolbutamide.
VilazodoneVilazodone may increase the hypoglycemic activities of Tolbutamide.
VildagliptinVildagliptin may increase the hypoglycemic activities of Tolbutamide.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Tolbutamide.
VogliboseVoglibose may increase the hypoglycemic activities of Tolbutamide.
VoriconazoleThe serum concentration of Tolbutamide can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Tolbutamide.
VorinostatThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Tolbutamide.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Tolbutamide.
WarfarinTolbutamide may increase the anticoagulant activities of Warfarin.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Tolbutamide.
ZafirlukastThe metabolism of Tolbutamide can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Tolbutamide.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Tolbutamide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Tolbutamide.
ZileutonThe metabolism of Zileuton can be decreased when combined with Tolbutamide.
ZimelidineZimelidine may increase the hypoglycemic activities of Tolbutamide.
ZiprasidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Tolbutamide.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Tolbutamide.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sulfonylurea receptor activity
Specific Function:
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name:
ABCC8
Uniprot ID:
Q09428
Molecular Weight:
176990.36 Da
References
  1. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA: Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74. [PubMed:18220763 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Proks P, Jones P, Ashcroft FM: Interaction of stilbene disulphonates with cloned K(ATP) channels. Br J Pharmacol. 2001 Mar;132(5):973-82. [PubMed:11226127 ]
  2. Smith PA, Proks P: Inhibition of the ATP-sensitive potassium channel from mouse pancreatic beta-cells by surfactants. Br J Pharmacol. 1998 Jun;124(3):529-39. [PubMed:9647478 ]
  3. Liu X, Singh BB, Ambudkar IS: ATP-dependent activation of K(Ca) and ROMK-type K(ATP) channels in human submandibular gland ductal cells. J Biol Chem. 1999 Aug 27;274(35):25121-9. [PubMed:10455193 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys. 1998 May 1;353(1):16-28. [PubMed:9578596 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys. 1998 May 1;353(1):16-28. [PubMed:9578596 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. [PubMed:10854830 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23